Analysis of Clonal Relationship Using Single-Cell Polymerase Chain Reaction in a Patient with Concomitant Mantle Cell Lymphoma and Multiple Myeloma

2001 ◽  
Vol 73 (3) ◽  
pp. 383-385 ◽  
Author(s):  
Motoko Yamaguchi ◽  
Toshiyuki Ohno ◽  
Eri Miyata ◽  
Hideki Toyoda ◽  
Kazuhiro Nishii ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Polymerase Chain Reaction ◽  
Mantle Cell Lymphoma ◽  
Single Cell ◽  
Cell Lymphoma ◽  
Chain Reaction ◽  
Clonal Relationship ◽  
Mantle Cell ◽  
Polymerase Chain

Mantle Cell Lymphoma

1999 ◽  
Vol 123 (12) ◽  
pp. 1182-1188 ◽  
Author(s):  
Rebecca C. Hankin ◽  
Susan V. Hunter
Keyword(s):  
Polymerase Chain Reaction ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Diagnostic Tests ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Molecular Diagnostic ◽  
Chain Reaction ◽  
Mantle Cell ◽  
Polymerase Chain

Abstract Objective.—This article summarizes the most useful ancillary immunohistochemical and molecular assays for use in the diagnosis of mantle cell lymphoma. Data Sources.—The English language literature was surveyed, with an emphasis on recent publications, for articles presenting key advances in the molecular characterization of mantle cell lymphomas and for series of cases testing the utility of molecular diagnostic tests. The authors' series of 26 small B-cell lymphomas, analyzed for the cyclin D1 protein by paraffin immunohistochemistry and for t(11;14) by polymerase chain reaction, is included. Conclusions.—Mantle cell lymphoma, a B-cell lymphoma now recognized in the 1994 Revised European-American Classification of Lymphoid Neoplasms (REAL) classification, is a relatively aggressive lymphoma with a poor prognosis. Its characteristic t(11;14)(q13;q32) translocation has a role in oncogenesis and has been exploited for molecular diagnostic tests, but these tests vary in sensitivity, specificity, and ease of use. Improved immunohistochemical tests are sufficient to confirm the diagnosis in most cases. Conventional cytogenetics and molecular diagnostic tests for t(11;14)—Southern blot and polymerase chain reaction analysis—may be helpful in selected cases, but are laborious or of limited sensitivity. Other methods, such as fluorescence in situ hybridization, need further development to provide faster, more sensitive diagnosis.

scholarly journals Advances in the assessment of minimal residual disease in mantle cell lymphoma

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Dayoung Jung ◽  
Preetesh Jain ◽  
Yixin Yao ◽  
Michael Wang
Keyword(s):  
Polymerase Chain Reaction ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Cell Lymphoma ◽  
Disease Detection ◽  
Chain Reaction ◽  
Minimal Residual Disease Detection ◽  
Mantle Cell ◽  
Polymerase Chain ◽  
Minimal Residual

Abstract The clinical impact of minimal residual disease detection at early time points or during follow-ups has been shown to accurately predict relapses among patients with lymphomas, mainly in follicular and diffuse large B cell lymphoma. The field of minimal residual disease testing in mantle cell lymphoma is still evolving but has great impact in determining the prognosis. Flow cytometry and polymerase chain reaction-based testing are most commonly used methods in practice; however, these methods are not sensitive enough to detect the dynamic changes that underline lymphoma progression. Newer methods using next-generation sequencing, such as ClonoSeq, are being incorporated in clinical trials. Other techniques under evolution include CAPP-seq and anchored multiplex polymerase chain reaction-based methods. This review article aims to provide a comprehensive update on the status of minimal residual disease detection and its prognostic effect in mantle cell patients. The role of circulating tumor DNA-based minimal residual disease detection in lymphomas is also discussed.

Sign in / Sign up

Export Citation Format

Share Document